Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This phase 2 study is designed to evaluate the safety, tolerability and efficacy of
allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager
blinatumomab in B-precursor ALL patients who have mixed chimerism (MC) or are MRD-positive
after allogeneic SCT and are refractory to at least one MRD- or MC-targeted therapy (i.e.
blinatumomab, DLI, tyrosine kinase inhibitors or other agents).